The Motley Fool··David Jagielski, CpaPfizer's Growth Engine Roars as Cancer Drugs Surge, but Patent Cliffs Loom
Pfizer's Q1 shows 22% growth from new products, with cancer drug Padcev surging 39%, but patent cliffs on major drugs threaten future revenues.
PFEpharmaceutical growthpatent cliff